Global nonalcoholic steatohepatitis (NASH) treatment market was valued at US$ XX Mn in 2017 and expected to grow at 15.0% Compound Annual Growth Rate (CAGR) over 2018 to 2024

Global nonalcoholic steatohepatitis (NASH) treatment market was valued at US$ XX Mn in 2017 and expected to grow at 15.0% Compound Annual Growth Rate (CAGR) over 2018 to 2024

 

Market Outline: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market

Nonalcoholic steatohepatitis (NASH) treatment or fatty liver disease develop in the nonalcoholic humans that causes the liver damage which is diagnostically similar to alcoholic hepatitis. Nonalcoholic steatohepatitis may also causes due to glucose intolerance, dyslipidemia, and obesity. NASH is a silent disease with few or no symptoms. Currently a few drugs are available in the market for the treatment of nonalcoholic steatohepatitis treatment.

 

Market Dynamics: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market

Increase in the prevalence of metabolic disorders such as diabetes and dyslipidemia are expected to drive the NASH Treatment Market. Moreover, rise in R&D for the innovation of novel therapeutics for NASH disease, promising pipeline products, and change in lifestyle are anticipated to boost the nonalcoholic steatohepatitis treatment market over the forecast period. However, lack of efficient disease diagnosis procedures in early stage, poor understanding of disease pathophysiology, and large medical unmet need may impede the growth of nonalcoholic steatohepatitis market.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/nonalcoholic-steatohepatitis-nash-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

 

Market Scope: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market

Global nonalcoholic steatohepatitis (NASH) treatment market is segmented based on the product type and distribution channel

Based on the product type, the market is segmented into the following:

  • Simtuzumab and Liraglutide
  • GFT 505
  • Vitamin E
  • Obeticholic Acid (INT-747)
  • Pioglitazone
  • Others

Based on the distribution channel, the market is segmented into the following:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/nonalcoholic-steatohepatitis-nash-treatment-market/#ulp-c654SbFYO64MsOhu

 

 

Regional Analysis: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market

Geographically, global nonalcoholic steatohepatitis (NASH) treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America nonalcoholic steatohepatitis (NASH) treatment market growth driven by increase in the prevalence of NASH disease due to rise in obesity and metabolic disorders (according to American Liver Foundation, approximately 12% of total population has NASH and 3% has advanced liver fibrosis due to NASH) and change in lifestyle are anticipated to fuel the market. Europe nonalcoholic steatohepatitis (NASH) treatment market expected to exhibit lucrative growth due to increase in the R&D for the innovation of newer drugs, rise in prevalence of NASH due to metabolic disorders, and increase in healthcare expenditure. However, a significant growth rate observed in Asia Pacific nonalcoholic steatohepatitis (NASH) treatment market owing to entry of market players into Asia Pacific region, large patient pool, and rise in healthcare expenditure are expected to bolster the market in the region.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/nonalcoholic-steatohepatitis-nash-treatment-market/#ulp-14mlyhjMGhVjZqa3

 

 

Competition Assessment: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market

Some of the players in the global nonalcoholic steatohepatitis (NASH) treatment market include:

  • Zydus Cadila (India)
  • Genfit SA (France)
  • AstraZeneca Plc (UK)
  • Gilead Sciences, Inc. (U.S.)
  • Conatus Pharmaceuticals, Inc. (U.S.)
  • Galmed Pharmaceuticals Ltd (Israel)
  • Immuron (Australia)
  • Intercept Pharmaceuticals, Inc. (U.S.)
  • Tobira Therapeutics, Inc. (U.S.)
  • Galectin Therapeutics, Inc. (U.S)

 

Notable Market Developments: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market

  • In December 2017, Galectin Therapeutics announced the Phase 2b clinical trial results of GR-MD-02 which showed significant results in NASH cirrhosis patients
  • In January 2018, Genfit started the clinical trials for Children with NASH disease in US with the drug elafibranor

 

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/nonalcoholic-steatohepatitis-nash-treatment-market/

 

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US):+1-866-598-1553

Website @https://www.precisionbusinessinsights.com

Leave a Reply